Diffuse large B-cell lymphomas with aberrations in MYC, BCL2 and/or BCL6 by genetic
alterations or protein expression represent a group of high grade B-cell lymphomas with …

MYC is a potent oncogene initially identified as the target of the t (8; 14)(q24; q32)
chromosome translocation in Burkitt lymphoma. MYC gene alterations have been identified …

Purpose Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC …

MYC rearrangements occur in 5% to 10% of diffuse large B-cell lymphomas (DLBCL) and
confer an increased risk to cyclophosphamide, hydroxydaunorubicin, oncovin, and …

Purpose Concerns regarding neurocognitive toxicity of whole-brain radiotherapy (WBRT)
have motivated development of alternative, dose-intensive chemotherapeutic strategies as …

The identification of activating NOTCH1 mutations in T cell acute lymphoblastic leukemia (T-
ALL) led to clinical testing of γ-secretase inhibitors (GSIs) that prevent NOTCH1 activation …

We investigated the therapeutic potential of JQ1, an inhibitor of the BET class of human
bromodomain proteins, in B-cell acute lymphoblastic leukemia (B-ALL). We show that JQ1 …

c-MYC is one of the most essential transcriptional factors, regulating a diverse array of
cellular functions, including proliferation, growth, and apoptosis. Dysregulation of c-MYC is …

Diffuse large B-cell lymphoma (DLBCL) is a clinically heterogeneous lymphoid malignancy
and the most common subtype of non-Hodgkin's lymphoma in adults, with one of the highest …

MYC alterations influence the survival of patients with diffuse large B-cell lymphoma. Most
studies have focused on MYC translocations but there is little information regarding the …